<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303975</url>
  </required_header>
  <id_info>
    <org_study_id>JM0019002</org_study_id>
    <nct_id>NCT04303975</nct_id>
  </id_info>
  <brief_title>The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma</brief_title>
  <official_title>An Explorative Study on the Association of High Sensitivity C-Reactive Protein (hsCRP) and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiarong Chen, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangmen Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to explore the association of high sensitivity&#xD;
      C-reactive protein (hsCRP) and radiotherapy(RT)-induced toxicity in patients with&#xD;
      nasopharyngeal carcinoma. In each patient, hsCRP levels in the pre- and post-RT plasma&#xD;
      samples will be measured according to the schedule we set.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hsCRP levels</measure>
    <time_frame>Through treatments completion，12 weeks</time_frame>
    <description>The hscrp levels in the plasma samples from each participant were measured at the following time points:&#xD;
at the time of diagnosis completion/before the initiation of the first neoadjuvant chemotherapy&#xD;
before the initiation of each neoadjuvant chemotherapy&#xD;
before the initiation of the first radiotherapy&#xD;
during radiotherapy, once a week&#xD;
1 week and 4weeks after the last radiotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through treatments completion，12 weeks</time_frame>
    <description>All adverse events were recorded during treatment(for example, oral mucositis, dermatitis).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Toxicity Due to Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Group 1: Patients with neoadjuvant chemotherapy</arm_group_label>
    <description>The patients of group1 will receive one of the following treatments:&#xD;
neoadjuvant chemotherapy &amp; concurrent chemoradiotherapy&#xD;
neoadjuvant chemotherapy &amp; radiotherapy&#xD;
neoadjuvant chemotherapy &amp; radiotherapy &amp; adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Patients without neoadjuvant chemotherapy</arm_group_label>
    <description>The patients of group2 will receive one of the following treatments:&#xD;
concurrent chemoradiotherapy&#xD;
concurrent chemoradiotherapy &amp; adjuvant chemoradiotherapy&#xD;
radiotherapy &amp; adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical measurements</intervention_name>
    <description>Only clinical parameters were recorded, no intervention was made.</description>
    <arm_group_label>Group 1: Patients with neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Group 2: Patients without neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with nasopharyngeal carcinoma during the conducting of this trail at&#xD;
        Jiangmen Central Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients were pathologically newly diagnosed with nasopharyngeal carcinoma and had no&#xD;
             previous history of other tumors&#xD;
&#xD;
          -  According to the treatment strategies of doctors, patients need to receive&#xD;
             radiotherapy with or without chemotherapy (for example, neoadjuvant chemotherapy,&#xD;
             concurrent chemotherapy, adjuvant chemotherapy) or targeted therapy&#xD;
&#xD;
          -  Willingness to sign the informed consent and return to enrolling institution for&#xD;
             follow-up and data collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients do not conform to the inclusion criteria&#xD;
&#xD;
          -  Pregnant or Nursing women&#xD;
&#xD;
          -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
             contraception&#xD;
&#xD;
          -  Vital organs dysfunction(for example, kidneys, heart, liver, lungs, brain)&#xD;
&#xD;
          -  Other contraindications or unsuitable conditions for radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jiarong Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Jiangmen Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiarong Chen, PhD</last_name>
    <phone>86-0750-3399003</phone>
    <email>garwingchan@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanghao Ruan</last_name>
    <email>ruanyanghao@126.com</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jiangmen Central Hospital</investigator_affiliation>
    <investigator_full_name>Jiarong Chen, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

